company background image
BBIO

BridgeBio PharmaNasdaqGS:BBIO Stock Report

Market Cap

US$7.3b

7D

-6.8%

1Y

32.5%

Updated

26 Sep, 2021

Data

Company Financials +
BBIO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

BBIO Overview

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.

Price History & Performance

Summary of all time highs, changes and price drops for BridgeBio Pharma
Historical stock prices
Current Share PriceUS$48.57
52 Week HighUS$36.20
52 Week LowUS$73.50
Beta0.73
1 Month Change-3.78%
3 Month Change-18.22%
1 Year Change32.49%
3 Year Changen/a
5 Year Changen/a
Change since IPO76.30%

Recent News & Updates

Shareholder Returns

BBIOUS BiotechsUS Market
7D-6.8%-2.3%0.1%
1Y32.5%26.0%35.3%

Return vs Industry: BBIO exceeded the US Biotechs industry which returned 26% over the past year.

Return vs Market: BBIO underperformed the US Market which returned 35.3% over the past year.

Price Volatility

Is BBIO's price volatile compared to industry and market?
BBIO volatility
BBIO Beta0.73
Industry Beta1.03
Market Beta1

Stable Share Price: BBIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BBIO's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015391Neil Kumarhttps://www.bridgebio.com

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1.

BridgeBio Pharma Fundamentals Summary

How do BridgeBio Pharma's earnings and revenue compare to its market cap?
BBIO fundamental statistics
Market CapUS$7.27b
Earnings (TTM)-US$495.27m
Revenue (TTM)US$62.74m

116.0x

P/S Ratio

-14.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BBIO income statement (TTM)
RevenueUS$62.74m
Cost of RevenueUS$109.00k
Gross ProfitUS$62.63m
ExpensesUS$557.89m
Earnings-US$495.27m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.31
Gross Margin99.83%
Net Profit Margin-789.46%
Debt/Equity Ratio-301.5%

How did BBIO perform over the long term?

See historical performance and comparison

Valuation

Is BridgeBio Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BBIO ($48.57) is trading below our estimate of fair value ($244.08)

Significantly Below Fair Value: BBIO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BBIO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BBIO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BBIO has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Future Growth

How is BridgeBio Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

21.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BBIO's revenue (60.8% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: BBIO's revenue (60.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BBIO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has BridgeBio Pharma performed over the past 5 years?

-50.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BBIO is currently unprofitable.

Growing Profit Margin: BBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BBIO is unprofitable, and losses have increased over the past 5 years at a rate of 50.8% per year.

Accelerating Growth: Unable to compare BBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: BBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is BridgeBio Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BBIO has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BBIO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BBIO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is BridgeBio Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Neil Kumar (41 yo)

6.42yrs

Tenure

US$10,054,909

Compensation

Dr. Neil Kumar, Ph D., is a Co-Founder and serves as Chief Executive Officer and a Member of Board of Directors BridgeBio Pharma, Inc. since April 2015. He serves as Director of Phoenix Tissue Repair, Inc....


CEO Compensation Analysis

Compensation vs Market: Neil's total compensation ($USD10.05M) is above average for companies of similar size in the US market ($USD6.40M).

Compensation vs Earnings: Neil's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BBIO's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: BBIO's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.4%.


Top Shareholders

Company Information

BridgeBio Pharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BridgeBio Pharma, Inc.
  • Ticker: BBIO
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.274b
  • Shares outstanding: 149.77m
  • Website: https://www.bridgebio.com

Number of Employees


Location

  • BridgeBio Pharma, Inc.
  • 421 Kipling Street
  • Palo Alto
  • California
  • 94301
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/26 22:03
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.